anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Intensive home treatment (IHT) has shown to be a feasible alternative to hospitalization for the management of acute psychiatric episodes, but there are no real-world studies assessing if patients with a first IHT use it again for the management of their recurrences. The objectives of this retrospective cohort study were to map the use ofacute treatment resources after the implementation of IHT in our territory through the establishment of trajectories of management, and to disentangle if there are profiles of patients who fit better each trajectory. We included the first 1000 episodes admitted to IHT, of which we selected those that corresponded to the first IHT of a patient (index admission). Trajectories after the index admission were: (T-A) absence of use of acute resources, (T-B) only IHT, and (T-C) at least one hospitalization. Follow-up ranged from 6 months to 6 years. We calculated the frequency of each trajectory and performed univariate analyses searching for associations between trajectory and clinical factors. Among those patients with psychiatric history (N = 659), 66.2% followedT-A, 11.2% T-B, and 22.6% T-C. The probability of following T-C was higher for patients with a psychotic disorder (pBonf = 0.018) and with previous hospitalizations (pBonf < 0.0001). Among those patients without psychiatric history (N = 168), 82.7% followed T-A, 6.6% T-B, and 10.7% T-C. The probability of following T-B was higher for those with a higher severity at the index admission (pBonf = 0.028). This study shows that some -or even all- recurrences of some subjects were successfully managed with IHT, providing real-world evidence for its use in acute psychiatric conditions.
Patients in both cohorts will receive SBRT using volumetric arc therapy. The prescribed dose is 30-54 Gy in 3 fractions over 1 week. Then patients in the control group (arm B) will be followed up regularly.
The invention belongs to biotechnology and medical field and discloses a new human epididymis specific expression sperm binding protein HEL-172 and preparation and application thereof. The invention discloses an amino acid sequence of the HEL-172 protein and provides a recombination expression vector carrying a DNA sequence for encoding the protein. The invention further discloses a method for preparing the protein and detecting the biological function of the HEL-172 protein. The protein is positioned at the back region of the head of a mature sperm, has expression in epididymis and spermary, heart, liver, spleen, kidney and stomach. A band of about 34 KD is detected in the epididymis by using Western blot. The HEL-172 protein can be used as a target protein for the research and development of immunity acyeterion as well as clinical diagnosis and treatment of male infertility. The relevant gene or protein detecting method based on the protein HEL-172 can be widely applied to the reproductive medicine research field.
Participants in the IPT-G condition will receive 12 group therapy sessions over 2 weeks as well as 2 individual (pre-group and 1-month booster sessions). In addition, 3 of the 12 group sessions will invite women to include their partners or other support people to bolster the woman's social support system and to reduce conflicts over how to react to the loss. This study adapted IPT for treatment of depression after perinatal loss.
FIELD: cosmetics, particularly, agents of gerontological action. SUBSTANCE: cream contains oil phase, emulsifiers, cross-linking components, biologically active additives, vitamin E, gerontological agent, conservants, perfume composition and water. Components are used in preset ratio. Used as a biologically active additive is extract of apple seeds in combination with solution of acetate tocopherol and magnesium sulfate. The cream reacts against natural thinning of dry aged skin and possesses antiinflammatory action healing damaged skin, regulates balance exchange of epidermis, and ensures water-retaining and gas-permeable protection of skin. EFFECT: higher efficiency. 1 cl, 2 tbl
ABSTRACT OF THE DISCLOSURE           A process for the separation and isolation of AHF, fibro-nectin and von Willebrand's ristocetin cofactor from blood plasma by adding a sulfated mucopolysaccharide to blood plasma to a con-centration of from about 0.05 to about 0.4 mg/ml of plasma, cool-ing the plasma to 0°C - 15°C, centrifuging the plasma to isolate a precipitate which forms and then removing the AHF-rich super-natant liquid from the precipitate.         The precipitate is washed in a slightly basic solution of dilute salts and then dissolved in a buffered solution of chao-trophic salts of the Hofmeister series having an ionic strength from 0.01 - 1.  Fibronectin is separated by chromotographic means from the dissolved precipitate which contains fibronectin and fibrinogen.         The dissolved precipitate may also be applied to a glass or plastic column containing a 4% agarose gel (eg. "Sepharose"?B or"Biogel"??-15m) in a 0.25 molar solution sodium phosphate titrat-ed to pH 7.0 with any base, preferably TRIS.  The von Willebrand's ristocetin cofactor elutes in the void volume of the column, where-as the fibronectin-rich fraction elutes later.  Both fractions may be collected and concentrated.         In a preferred embodiment, 0.20 mg of sodium heparin per milliliter of human plasma is employed with the heparinized plasma solution cooled for 3 hours at a temperature of 2°C - 4°C.     *    Trademark **   Trademark
A method and system for a generic mechanism for adjudication of claims in a claims processing system. The generic mechanism comprises a Web services module, a Web portal, a batch loader, a claim database, and an interface engine. The Web services module, the Web portal, and the batch loader are used by medical providers to submit claims. Upon submission, claim information is converted to generic messages and sent to the interface engine. The interface engine validates the generic messages using a claim schema, prior to converting them to an internal message format, and sending them to a clearing house application. When messages are adjudicated by the clearing house application, they are returned to the interface engine, where the return messages are converted back to generic messages and validated against a return message schema. Valid messages along with any error are returned to the medical providers and submitted for payment approval.
The proposed study is a randomized, controlled, double-masked trial comparing the effect of postpartum acetaminophen and ibuprofen on blood pressure among women with preeclampsia. Study participants will be randomized to receive either acetaminophen or ibuprofen for mild postpartum pain control. Study participants, study personnel and providers will be blinded to randomization status of study participants.

Potential study participants will be enrolled when they are diagnosed with a severe hypertensive disorder of pregnancy. This will usually occur prior to delivery, but may occur up to 6 hours after delivery. Patients diagnosed with preeclampsia without severe features will also be approached and enrolled at the time of diagnosis in anticipation for possible progression to preeclampsia with severe features. Once enrolled, study participants will not be randomized until delivery, at which time they will be randomized to receive either acetaminophen or ibuprofen for mild postpartum pain. Both groups will have available oxycodone for moderate to severe pain, per our routine. Study group allocation will only be known by the investigational pharmacy. The ibuprofen and acetaminophen will be made to appear identical to each other and will be unmarked through encapsulation. Block randomization will be used to ensure equal allocation to the two study arms.

For the duration of study participation, study participants will undergo postpartum monitoring with vital sign measurements (including blood pressure) every 4 hours, pain assessment with each administration of study medication, as well as daily evaluation of laboratory studies until they have normalized to the satisfaction of their provider. Study participants will receive the study drug every 6 hours from the time of delivery until hospital discharge, unless they refuse. Study participation will be complete upon hospital discharge. Study participants will be contacted by a study team member 6 weeks after delivery to ask about any additional complications or symptoms requiring visits to the emergency department or hospital readmission. Descriptive factors and clinical outcomes will be extracted from the medical record and de-identified by study personnel during each day of study participation.
Participants randomized to the Jom-TestPlus group will have access to all Jom-TestPlus features, including: assessment center; online registration; risk calculator; HIVST kit order, management, and monitoring; automated reminders; real-time e-counseling (eHIVST, active referral services); chemsex-related harm reduction services (screening, chemsex e-counseling, PartyPack ordering), chat function (ability to chat with counselors and research staff); and knowledge center (multimedia library on information and resources on HIV testing, PrEP, treatment, risks, and chemsex). Participants will follow a defined pathway to accessing HIVST kit ordering, e-counseling, and subsequent O2O linkage to clinical services.
Of the total number of patients who received Lotrel in U.S. clinical studies of Lotrel, over 19% were 65 or older while about 2% were 75 or older. Overall differences in effectiveness or safety were not observed between these patients and younger patients. Clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

Benazepril and benazeprilat are substantially excreted by the kidney. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

Amlodipine is extensively metabolized in the liver. In the elderly, clearance of amlodipine is decreased with resulting increases in peak plasma levels, elimination half-life and area-under-the-plasma-concentration curve. Thus a lower starting dose may be required in older patients [see Dosage and Administration (2)].
The present invention relates to new molecular design that allows micelles to report their activation and disassembly by an enzymatic trigger. The molecular design is based on introduction of a labeling moiety selected from a fluorescent dye, a dark quencher, combinations of dyes or dyes/quenchers, and a fluorinated moiety (a 19F-magenetic resonance (MR) probe for turn ON/OFF of a 19F-MR signal) through covalent binding to the focal point of amphiphilic polymer-dendron hybrids with the labeling moiety. At the assembled micellar state, the dyes are closely packed and hence the probability for intermolecular interactions increases significantly, leading to alteration of the fluorescent properties (signal quench or shift) or the 19F-MR signal (OFF state) of the micelles. Upon enzymatic cleavage of the hydrophobic end-groups from enzyme-responsive dendron, the polymers become hydrophilic and disassemble. This structural change is then translated into a spectral change as dye-dye interactions are halted and the dyes regain their intrinsic fluorescent properties, or alternatively by turn ON the 19F-MR signal. The high modularity of the design allows the introduction of various types of dyes and thus enables rational adjustment of the spectral response. Two major types of responses are described: Turn-On/Off and spectral shift, depending on the type of labeling dye. The present invention further provides methods of use of the hybrid delivery system and to a kit comprising the same.
Children with confirmed asymptomatic or pauci-symptomatic COVID infection will be recruited in pediatric emergency departments, among siblings of COVID-19+ pediatric patients or through the blood collection centers set up by the occupational health services. A single visit will be scheduled at the hospital (for clinical examination, biology, immunology, virology measurements) and a phone call performed at day 14.
Chronic stroke is often accompanied by tactile impairments that contribute to long-term disability in activities of daily living. While new rehabilitative interventions recently became available in the motor domain by using transcranial direct current stimulation (tDCS), there is no generally accepted treatment for tactile impairments after chronic stroke. Previous studies in healthy volunteers demonstrated that tactile acuity and haptic skills can be improved by applying a passive learning protocol to the fingertip (peripheral high-frequency stimulation, pHFS). Based on these findings, the purpose of this protocol is to enhance the beneficial effect of pHFS on implicit tactile and haptic learning in chronic stroke patients by a combined application of pHFS with tDCS (pHFS+tDCS) applied to the somatosensory cortex of the affected hemisphere. This approach might identify novel strategies to enhance functional recovery after stroke and might provide deeper insight into mechanistic information on the neural substrates involved in these behavioral gains. Primary outcome measures will be performance in a tactile grating orientation discrimination task (GOT) and in a haptic object recognition task. In order to obtain descriptive preliminary information on the relation between sensory improvements and motor deficits in chronic stroke patients, secondary outcome measures will be fine motor tasks such as a tapping task and a pegboard test (PBT) that require manual dexterity, handeye coordination, steadiness, and perceptual motor skills. To identify the operating mechanisms underlying hypothesized performance improvements after pHFS+tDCS, we will use paired-pulse protocols to evaluate changes in cortical excitability as well as fMRI in a subset of patients to identify cortical map reorganization in primary (SI) and secondary (SII) somatosensory cortex as well as in primary motor cortex (MI). Healthy volunteers will be tested (a) since there are no data available on performance of the haptic task in healthy subjects, (b) to obtain descriptive information on the influence of our interventions on this task for hypothesis generation purposes in our future investigations, and (c) because sensorimotor performance in the non-paretic hand of stroke patients is often not normal and therefore a poor sole control for performance of the paretic hand. Studies in chronic stroke patients will help address the main experimental hypothesis.
The innovative treatment strategy described here utilizes configurable microscopic medical payload delivery devices to act as a transport means to deliver chemotherapy molecules to specific cell types in the body. Utilizing probes present on the exterior of the transport device, transport device locates specific target cell types in the body. Once a specific target cell type has been encountered, the configurable microscopic medical payload delivery device inserts its payload of chemotherapy molecules into the target cell type. By delivering chemotherapy molecules into specific cells, the growth of the specific cells can be stifled. Delivering chemotherapy molecules into specific cancer cells inhibits the rate of growth and rate of cell reproduction of the cancer cells. Utilizing configurable microscopic medical payload delivery devices to insert chemotherapy into targeted cancer cells or inflammatory cells effectively manages cancer, inflammatory arthritis and other inflammatory conditions, while preventing unwanted side effects.
Bone is the most common metastatic site for breast cancer. The estrogen-related receptor alpha (ERRα) has been implicated in breast cancer cell dissemination to the bone from the primary tumor. However, its role after tumor cell anchorage in the bone microenvironment remains elusive. Here, the inventors reveal that ERRα inhibits the progression of bone metastases of breast cancer cells by increasing the immune activity of the bone microenvironment. Over-expressing ERRα in breast cancer bone metastases induced the expression of the chemokines CCL17 and CCL20 and repressed the production of transforming growth factor beta 3 (TGF-ß3). Subsequently, CD8 +  T lymphocytes recruited to the bone metastases escaped TGF-ß signalingcontrol were endowed with exacerbated cytotoxic features and metastases were strongly decreased. The clinical relevance of the findings in mice was confirmed in over 248 breast cancer patients. Thus, the inventors propose to consider ERRα expression, as a biomarker predictive of BM response to immunotherapies and /or as a good prognosis marker in BM progression once established, opening the path towards to the clinical use of ERRαagonist to relieve patients with ERRα positive BM after primary tumor resection.
A dosage form for delivering an antiepileptic drug to a gastrointestinal tract includes a compartment containing a drug formulation layer which comprises an antiepileptic drug. The dosage form further includes a semipermeable wall surrounding the compartment. The semipermeable wall has a passageway that allows communication between the compartment and an exterior of the dosage form. An internal lamina is formed on an inner surface of the semipermeable wall. The internal lamina is substantially soluble in water. The internal lamina in a hydrated state forms a gelatinous layer that lubricates the semipermeable wall, thereby preventing crack formation in the semipermeable wall while the dosage form is dispensing the drug.
The invention provides a traditional Chinese medicine for treating insufficient secretion of human milk due to stagnation of liver qi. The traditional Chinese medicine is composed of the following raw materials in parts by weight: 9 to 18 parts of cowherb seed, 6 to 12 parts of red peony root, 6 to 15 parts of tetrapanax papyriferus, 10 to 15 parts of dandelion, 3 to 6 parts of processed pangolin, 6 to 12 parts of pollen, 8 to 12 parts of radix rhapontici, 5 to 10 parts of loofah sponge, 9 to 18 parts of fried malt, 9 to 15 parts of onion stalk, and 8 to 12 parts of bryophyllum pinnatum. The invention also provides a preparation method of the traditional Chinese medicine. The traditional Chinese medicine has the functions of moving qi, activating blood, soothing the liver, relieving depression, generating essence, nourishing blood, and promoting secretion of milk, and is capable of effectively promoting secretion of milk and growth of breasts. Natural components, which can be taken as food and medicine and have the functions of activating blood and freeing collaterals, are used to prepare the traditional Chinese medicine; the traditional Chinese medicine can dredge the mammary ducts, and the channels for discharge human milk is dredged, so the human milk can be successfully discharged. The problem of insufficient secretion of human milk is radically solved, and the root and symptoms are all treated.
According to one aspect, there is provided a server for use in evaluating a monitoring function to determine if a trigger condition is satisfied. The server comprises a processing unit and a memory unit. The memory unit is for storing a current monitoring state (Ss) of the server or an encrypted current monitoring state (S) of the monitoring function, the current monitoring state (Ss) of the server relating to the current monitoring state (S) of the monitoring function that is based on an evaluation of one or more previous events. The processing unit is configured to receive an indication of a first event from a first client node and evaluate the monitoring function to determine if the first event satisfies the trigger condition. The evaluation is performed using a privacy-preserving computation (PPC), with the server providing the current monitoring state (Ss) of the server as a first private input to the PPC or the encrypted current monitoring state (S) of the monitoring function as a first input to the PPC, and the first client node providing the first event or an encryption thereof as a private input to the PPC. The evaluation of the monitoring function provides an encrypted updated monitoring state (S') of the monitoring function or an updated monitoring state (Ss') of the server as an output of the monitoring function and an indication of whether the first event satisfies the trigger condition.
The U.S. is grappling with an opioid epidemic, with millions of adults on long-term opioid therapy (LTOT). Although patients often report pain relief and improved daily function with opioids, research shows no significant differences in short-term outcomes between opioid and non-opioid users, as well as no long-term opioid benefits. This scoping review aims to identify lesser-known side effects of long-term opioid use and increase awareness of them, allowing healthcare providers and patients to better assess the risks and benefits of opioid use. Our data search from PubMed and Google Scholar used keywords related to opioids, chronic pain, hypogonadism, endocrinopathies, cancer progression, cardiovascular events, renovascular events, sleep disturbances, mood disorders and others, narrowing down to English-language full articles published from January 2018 to April 2023. This review emphasizes the probable serious adverse consequences of long-term opioid use on various body systems in patients with chronic pain. Given the lack of long-term benefits and significant adverse effects, our review underscores the critical need for healthcare providers to include these risks in discussions with patients when considering the long-term use of opioid therapy.
4.1 Pregnancy and Premenopausal Women

Anastrozole may cause fetal harm when administered to a pregnant woman and offers no clinical benefit to premenopausal women with breast cancer. Anastrozole is contraindicated in women who are or may become pregnant. There are no adequate and well-controlled studies in pregnant women using anastrozole. If anastrozole is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus or potential risk for loss of the pregnancy [see Use in Specific Populations ( 8.1)].

4.2 Hypersensitivity

Anastrozole is contraindicated in any patient who has shown a hypersensitivity reaction to the drug or to any of the excipients. Observed reactions include anaphylaxis, angioedema, and urticaria [see Adverse Reactions ( 6.2)].